• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
GSK-461364

GSK-461364

Product ID G7241
Cas No. 929095-18-1
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $127.90 In stock
5 mg $216.20 In stock
10 mg $337.60 In stock
25 mg $601.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

GSK-461364 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for solid tumor cancers. GSK-461364 displays anticancer chemotherapeutic activity as well as anticoagulant activity. This compound inhibits glioblastoma cell proliferation, invasion, and colony formation and induces apoptosis and G2 phase cell cycle arrest.

Product Info

Cas No.

929095-18-1

Purity

≥99%

Formula

C27H28F3N5O2S

Formula Wt.

543.60

IUPAC Name

5-{6-[(4-Methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl}-3-{(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy}-2-thiophenecarboxamide

Solubility

Ethanol 30 mg/mL (55.18 mM) DMSO 10 mg/mL (18.39 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

G7241 MSDS PDF

Info Sheet

G7241 Info Sheet PDF

References

Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs. 2013 Nov;24(10):999-1006. PMID: 23949254.

Pezuk JA, Brassesco MS, Morales AG, et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Ther. 2013 Sep;20(9):499-506. PMID: 23887645.

Olmos D, Barker D, Sharma R, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30. PMID: 21459796.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O7053

    L-Ornithine Hydrochloride

    Non-proteinogenic amino acid, L-arginine metabo...

    ≥98%
  • T162051

    Tebipenem

    Broad-spectrum antibiotic

    ≥99%
  • A9813

    AZD-8931

    Inhibitor of EGFR, HER2, and HER3.

    ≥98%
  • F4532

    Flibanserin

    5-HT1A agonist, 5-HT2A antagonist.

    ≥97%
  • C9615

    Cyclosporin B

    Cyclic peptide; calcineurin inhibitor.

    ≥95%
  • D324090

    Diclofenac Impurity C

    Impurity of diclofenac

    ≥98%
  • E8657

    Evodiamine

    Indole alkaloid found in Evodia rutaecarpa; top...

    ≥98%
  • E7230

    Ethambutol Dihydrochloride

    Arabinosyl transferase inhibitor.

    ≥98%
  • G1408

    GDC-0449

    Smo inhibitor.

    ≥98%
  • D0005

    Dabrafenib Mesylate

    B-Raf and c-Raf inhibitor.

    ≥98%
  • G733400

    GSK-2578215A

    Selective inhibitor of LRRK2.

    ≥98%
  • S824766

    Sutezolid

    Bactericidal.

    ≥98%
  • C0167

    Carbenoxolone

    Synthetic glycyrrhetinic acid derivative; 11β-...

    ≥98%
  • R2514

    RGDV

    Tretraeptide, binds cell surface integrins.

    ≥98%
  • C9881

    Cytochalasin D

    Mycotoxin produced by Aspergillus; actin polyme...

    ≥98%
  • T6803

    Trandolapril

    ACE inhibitor.

    ≥98%
  • P2858

    4-α-Phorbol-12-myristate-13-acetate

    Negative control for PKC activation.

    ≥98%
  • T5996

    Tozasertib

    AurK, FLT3, Abl inhibitor.

    ≥98%
  • M1575

    7-Methyl-6-mercaptopurine

    Thiopurine antimetabolite; PRPP amidotransferas...

    ≥87%
  • T1855

    Tentoxin

    Cyclic peptide mycotoxin produced by Alternaria...

    ≥98%, HPLC

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only